首页 | 本学科首页   官方微博 | 高级检索  
   检索      


Highly variable incidence of cystic fibrosis and different mutation distribution among different Jewish ethnic groups in Israel
Authors:Eitan Kerem  Yoram M Kalman  Yaacov Yahav  Tzipora Shoshani  Dvora Abeliovich  Amir Szeinberg  Joseph Rivlin  Hanna Blau  Asher Tal  Lea Ben-Tur  Chaim Springer  Arie Augarten  Simon Godfrey  Israela Lerer  David Branski  Moshe Friedman  Batsheva Kerem
Institution:(1) Shaare Zedek Medical Center, Jerusalem, Israel;(2) Department of Genetics, Life Sciences Institute, The Hebrew University Jerusalem, 91904, Israel;(3) Shiba Medical Center, Tel Aviv, Isreal;(4) Hadassah Medical Center, Jerusalem, Israel;(5) Carmel Medical Center, Haifa, Israel;(6) Belinson Medical Center, Petach Tikva, Israel;(7) Soroka Medical Center, Beer Sheva, Israel;(8) Rambam Medical Center, Haifa, Israel
Abstract:The incidence of cystic fibrosis (CF) and the frequency of disease-causing mutations varies among different ethnic and geographic populations. The Jewish population around the world is comprised of two major ethnic groups; Ashkenazi and non-Ashkenazi. The latter is further classified according to country of origin. In this study, we analyzed the incidence of CF and the distribution of CF mutations in the general Jewish population in Israel and in most of the Jewish ethnic subgroups. The disease frequency varies considerably among the latter. Among Ashkenazi Jews, the frequency of CF is 1ratio3300, which is similar to the frequency in most Caucasian populations. Among non-Ashkenazi Jews, the disease occurs at a similar frequency among Jews from Libya (1ratio2700), Georgia (1ratio2700), Greece and Bulgaria (1ratio2400), but is rare in Jews from Yemen (1ratio8800), Morocco (1ratio15000), Iraq (1ratio32000), and Iran (1ratio39000). So far, only 12 mutations have been identified in Israeli Jews, and this enables the identification of 91% of the CF chromosomes in the entire Jewish CF population. However, in each Jewish ethnic group, the disease is caused by a different repertoire of mutations. The frequency of identified mutations is high in Ashkenazi Jews (95%), and in Jews originating from Tunisia (100%), Libya (91%), Turkey (90%), and Georgia (88%). However, a lower frequency of mutations can be identified in Moroccan (85%), Egyptian (50%), and Yemenite (0%) Jews. For genetic counseling of a Jewish individual, it is necessary to calculate the residual risk according to ethnic origin. Carrier screening of healthy Jewish individuals is currently feasible for Ashkenazi Tunisian, Libyan, Turkish, and Georgian Jews. These results provide the required information for genetic counseling of Jewish CF families and screening programs of Jewish populations worldwide.
Keywords:
本文献已被 SpringerLink 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号